Glimepiride
Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
Glimepiride is a third-generation sulfonylurea used for type 2 diabetes management. It is preferred over glyburide in many patients due to its once-daily dosing, lower risk of hypoglycemia, and potentially less weight gain. It is often combined with metformin or other antidiabetic agents.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
Glimepiride is a third-generation sulfonylurea used for type 2 diabetes management. NutriStack rates the supporting evidence as strong. Common adult dosing is 1–8 mg once daily with first main meal (as prescribed by your physician), though a prescriber sets the actual dose. This profile indexes 10 sources.
- Lowers HbA1c by 1.0–1.5%
- Once-daily dosing improves adherence6
- Lower hypoglycemia risk compared to glyburide
- Relatively weight-neutral among sulfonylureas
- Inexpensive
The bottom line
Evidence rating strong. Most-documented uses: lowers hba1c by 1.0–1.5%, once-daily dosing improves adherence, lower hypoglycemia risk compared to glyburide. 10 sources indexed (2013–2025), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Binds to the sulfonylurea receptor SUR1 on pancreatic beta cells, closing ATP-sensitive potassium channels and triggering insulin release via calcium-dependent exocytosis. Unlike older sulfonylureas, glimepiride has faster association and dissociation from the receptor, which may explain its lower hypoglycemia risk. Also enhances peripheral insulin sensitivity through increased GLUT4 transporter activity.8
Dosing & protocol.
Take with breakfast or the first main meal of the day to reduce hypoglycemia risk.4
Full safety detail.
Side effects
- Hypoglycemia (lower risk than glyburide)
- Weight gain
- Dizziness
- Nausea
- Headache
- Allergic skin reactions
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Meta-analyses & systematic reviews
2- 1Efficacy and Safety of Gliclazide versus Glimepiride in T2DM Patients: A Systematic ReviewPMIDBansal R, Kant R, Bahurupi Y et al. · Indian journal of endocrinology and metabolism · 2025
Bansal R, Kant R, Bahurupi Y et al.. Efficacy and Safety of Gliclazide versus Glimepiride in T2DM Patients: A Systematic Review. Indian journal of endocrinology and metabolism. 2025
- 2The Clinical Pharmacokinetics and Pharmacodynamics of Glimepiride-A Systematic Review and Meta-AnalysisPMIDAzhar M, Alasmari MS, Zamir A et al. · Pharmaceuticals (Basel, Switzerland) · 2025
Azhar M, Alasmari MS, Zamir A et al.. The Clinical Pharmacokinetics and Pharmacodynamics of Glimepiride-A Systematic Review and Meta-Analysis. Pharmaceuticals (Basel, Switzerland). 2025
Randomized controlled trials
3- 3Efficacy and safety of pioglitazone, empagliflozin and glimepiride as third-line agents in patients with type 2 diabetes inadequately controlled with metformin and DPP-4 inhibitors: A multicentre, phase 4 randomized controlled trialPMIDCho YK, Cho JH, Hong SM et al. · Diabetes, obesity & metabolism · 2025
Cho YK, Cho JH, Hong SM et al.. Efficacy and safety of pioglitazone, empagliflozin and glimepiride as third-line agents in patients with type 2 diabetes inadequately controlled with metformin and DPP-4 inhibitors: A multicentre, phase 4 randomized controlled trial. Diabetes, obesity & metabolism. 2025
- 4Fixed dose combination of dapagliflozin, glimepiride and extended-release metformin tablets in patients with type 2 diabetes poorly controlled by metformin and glimepiride: A phase III, open label, randomized clinical study in IndiaPMIDSahay R, Gangwani D, Singh M et al. · Diabetes, obesity & metabolism · 2025
Sahay R, Gangwani D, Singh M et al.. Fixed dose combination of dapagliflozin, glimepiride and extended-release metformin tablets in patients with type 2 diabetes poorly controlled by metformin and glimepiride: A phase III, open label, randomized clinical study in India. Diabetes, obesity & metabolism. 2025
- 5Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 studyPMIDNauck M, Frid A, Hermansen K et al. · Diabetes, obesity & metabolism · 2013
Nauck M, Frid A, Hermansen K et al.. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes, obesity & metabolism. 2013
Reference material
5- 6Schernthaner G et al. GUIDE study: double-blind comparison of once-daily glimepiride and glipizide in type 2 diabetes. Eur J Clin Invest. 2004;34(8):535-542.Source linkedPMID
- 7American Diabetes Association. Standards of Medical Care in Diabetes, 2022. Diabetes Care. 2022;45(Suppl 1):S1-S264.Source linkedPMID
- 8Gao H et al. Evaluation of three mechanisms of action (SGLT2 inhibitors, GLP-1 receptor agonists, and sulfonylureas) in treating type 2 diabetes with heart failure: a systematic review and network meta-analysis of RCTs. Front Endocrinol (Lausanne). 2025.Source linkedPMID
- 9Rosenstock J, Kahn SE, Johansen OE et al.. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. JAMA. 2019Source linkedPMID
- 10Nauck M, Frid A, Hermansen K et al.. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes care. 2009Source linkedPMID
Common questions.
Quick answers about Glimepiride, drawn from the data on this page.
What is Glimepiride?
Glimepiride is a third-generation sulfonylurea used for type 2 diabetes management. It is preferred over glyburide in many patients due to its once-daily dosing, lower risk of hypoglycemia, and potentially less weight gain. It is often combined with metformin or other antidiabetic agents.
What is Glimepiride used for?
Commonly cited benefits of Glimepiride include: Lowers HbA1c by 1.0–1.5%; Once-daily dosing improves adherence; Lower hypoglycemia risk compared to glyburide; Relatively weight-neutral among sulfonylureas; Inexpensive. NutriStack rates the overall evidence as strong.
What is a typical dose of Glimepiride?
A typical adult dose of Glimepiride is 1–8 mg once daily with first main meal (as prescribed by your physician). The commonly recommended form is Oral tablet. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Glimepiride?
Reported side effects include hypoglycemia (lower risk than glyburide), weight gain, dizziness, nausea, headache, allergic skin reactions. This is educational information; check with a healthcare professional before use.
How strong is the evidence for Glimepiride?
NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Glimepiride in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.